A ‘GENERIC’ MARKET STRATEGY FOR TODAY AND TOMORROW
Once a drug comes off patent, generic drug manufacturers such as BioPharmcor, can start to produce their own version of the drug at a fraction of the cost.
In large developed markets for generic pharmaceuticals, it is estimated that generic medicines save the consumer today billions of dollars at retail pharmacies. That ‘saving’ figure rises dramatically when one considers the use of generic drugs by hospitals.
According to current market data, the total generic drug market is expected to reach approximately USD$ 380.60 billion by 2021, growing at a compound annual growth rate (CAGR) of around 10.8% between 2016 and 2021.The Men’s Health component of the global generic drugs market will represent about 4-5% of the total market or approximately USD$17.1 billion.
Upon receiving market approvals for Tadalafil we will initiate a unique product marketing strategy aimed at garnering a competitive market position in the generic drug market aimed at advancing men’s health. Biopharmcor's product line is focused on the two most prevalent Men's Health issues, namely erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) which causes difficulties in urination. The urinary difficulties, mostly commonly referred to as lower urinary tract symptoms (LUTs), significantly decrease quality of life.
Both ED and BPH/LUTs are common as men age, with more than 50% of men suffering from ED, BPH/LUTs, or both at the same time. Biopharmcor's generic Men's Health medications have been specifically selected to allow for the best treatment response and patient safety, and are the first-line therapy options for ED and BPH/LUTs as determined by both European and North American guidelines for treatment of these disorders.
By lowering the costs of providing therapeutic treatment for men suffering from urologic disorders, BioPharmcor’s product line of generic ED and BPH drugs will find burgeoning consumer markets throughout North America, the EU and other global markets.